| Cat. No. |
Product Name |
CAS No. |
Information |
| H9599 |
BLU-945
|
2660250-10-0 |
BLU-945 is a potent, mutant-selective inhibitor of EGFR T790M/C797S and EGFR+/T790M mutations (IC50<1 nM);BLU-945 achieves potent EGFR pathway inhibition in NCI-H1975 EGFRL858R/T790M, Ba/F3 EGFRL858R/T790M/C797S, and Ba/F3 EGFRex19del/T790M/C797S cell lines and a large window relative to EGFRWT inhibition.Oral administration of BLU-945 to tumor-bearing mice demonstrated potent EGFR pathway inhibition and anti-tumor activity at well-tolerated doses in the subcutaneous NCI-H1975 CDX model, and osimertinib-resistant CDX and PDX models. |
| H9388 |
Chiauranib
|
1256349-48-0 |
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM;Chiauranib has strongly anticancer effects. |
| H9291 |
Almonertinib hydrochloride
|
2134096-03-8 |
Almonertinib is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity;Upon administration, HS-10296 binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. |
| H9290 |
Almonertinib
|
1899921-05-1 |
Almonertinib is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity;Upon administration, HS-10296 binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. |
| H9214 |
CA-170
|
1673560-57-0 |
CA-170 is a first-in-class oral small molecule, is capable of selectively and potently antagonizing the negative immune checkpoints V-domain Ig suppressor of T-cell activation (VISTA) and PD-L1 with activities of 17 nM and 37 nM respectively. |
| H9049 |
TNO155
|
1801765-04-7 |
TNO155 is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). TNO155 has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors. |
| H8966 |
Rezivertinib
|
1835667-12-3 |
Rezivertinib is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutations T790M and L858R, as well as exon 19 deletion, with potential antineoplastic activity; Upon administration, rezivertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, BPI-7711 may have therapeutic benefits in tumors with T790M-mediated drug resistance. |
| H8959 |
Palcitoclax
|
1619923-36-2 |
Palcitoclax is a Bcl-X and Bcl-2 protein inhibitors. |
| H8888 |
Taletrectinib
|
1505515-69-4 |
Taletrectinib(DS-6051b,AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others; Taletrectinib (DS6051b/AB-106) is a highly selective type I ROS1/NTRK inhibitor. Taletrectinib demonstrates an enzymatic inhibition concentration at 50% (IC50) against ROS1, NTRK1, NTRK2, and NTRK3 of 0.207 nmol/L, 0.622 nmol/L, 2.28 nmol/L, and 0.980 nmol/L, respectively . |
| H8887 |
Taletrectinib free base
|
1505514-27-1 |
Taletrectinib free base(DS-6051b,AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others; Taletrectinib (DS6051b/AB-106) is a highly selective type I ROS1/NTRK inhibitor. Taletrectinib demonstrates an enzymatic inhibition concentration at 50% (IC50) against ROS1, NTRK1, NTRK2, and NTRK3 of 0.207 nmol/L, 0.622 nmol/L, 2.28 nmol/L, and 0.980 nmol/L, respectively . |
$ USD
Select Your Country or Region